Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.38 |
| ▸ | KLK1 | P06870 | 1/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4123703 | 0.81 | TBXAS1 (0.37) | TBXAS1KLK1KLK5FDPSFPR2 | |
| SCHEMBL10838551 | 0.76 | TBXAS1 (0.42) | TBXAS1KLK1KLK5FDPSFPR2 | |
| SCHEMBL18806402 | 0.75 | FDPS (0.41) | TBXAS1FDPSFPR2GAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL10837657 | 0.74 | TBXAS1 (0.44) | TBXAS1KLK1KLK5FDPSFPR2 | |
| SCHEMBL7431942 | 0.74 | TBXAS1 (0.41) | TBXAS1KLK1KLK5FDPSFPR2 | |
| SCHEMBL14194797 | 0.74 | TBXAS1 (0.41) | TBXAS1KLK1KLK5FDPSFPR2 | |
| SCHEMBL4688922 | 0.72 | TBXAS1 (0.43) | TBXAS1FDPSFPR2GAASMN1; SMN2 | |
| SCHEMBL4688926 | 0.72 | TBXAS1 (0.43) | TBXAS1FDPSFPR2GAASMN1; SMN2 | |
| SCHEMBL12590256 | 0.71 | FPR2 (0.39) | TBXAS1KLK1KLK5FDPSFPR2 | |
| SCHEMBL12085920 | 0.71 | FPR2 (0.39) | TBXAS1KLK1KLK5FDPSFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. | 2005-08-25 | — | — | US | claimed |
| US-7511145-B2 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | HAVCR2, MAVS, ZC3HAV1 | TBXAS1 638/4885KLK1 4621/4885KLK5 4094/4885 |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | HAVCR2, MAVS, ZC3HAV1 | TBXAS1 638/4885KLK1 4621/4885KLK5 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.